Background & Aims: The gradual accumulation of hepatic fibrosis in chronic liver disease results in clinical complications. The rate of hepatic fibrosis score progression (RFSP) in predicting clinical outcomes was assessed by extending the 4-year Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial to include preenrollment liver biopsies.
Methods: The RFSP was calculated from the linear regression slope of Ishak fibrosis score vs time in 457 patients with liver biopsies (≥10-mm length) prior to the HALT-C Trial (575 biopsies) plus 1101 on-study biopsies (total 1676 biopsies). Individual slopes were calculated if duration from first to last biopsy was > 4 years.
Results: The RFSP as average fibrosis score vs average time in intervals (0-3 and >3 years prestudy, screening, month 24 and 48 on-study) in 455 patients in cohorts of baseline Ishak score ranged from 0.005 with Ishak score 2 to 0.124 with Ishak 6. The RFSP in individual patients (-0.35 to +0.97 Ishak units/year) had a mean of 0.12 ± 0.23 in 344 patients with prestudy and on-study biopsies (group A) and only 0.17 ± 0.22 in 169 with prestudy and screening biopsies (group B). Group A patients with RFSP slope ≥ 0.2 (95 patients, 27.6%) had higher 7-year cumulative rates of non-hepatocellular carcinoma outcomes (46% vs 8%, respectively) and with a hepatocellular carcinoma (10% vs 3%, respectively) than RFSP slope < 02 (249 patients, 72.4%) (P < .0001). RFSP and screening Ishak score correlated independently (P <.0001) with clinical outcomes in multivariate analysis.
Conclusions: Rapid RFSP (>0.2), which occurred in 26.7% of HALT-C Trial patients, correlated strongly with clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773843 | PMC |
| http://dx.doi.org/10.1053/j.gastro.2011.06.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
PLoS One
April 2023
Division of Gastroenterology, University of Washington, Seattle, Washington, United States of America.
Branched chain amino acids (BCAA) supplementation may reduce the incidence of liver failure and hepatocellular carcinoma in patients with cirrhosis. We aimed to determine whether long-term dietary intake of BCAA is associated with liver-related mortality in a well-characterized cohort of North American patients with advanced fibrosis or compensated cirrhosis. We performed a retrospective cohort study using extended follow-up data from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial.
View Article and Find Full Text PDFA multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers.
Stat Med
June 2022
Biostatistics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
The early detection of hepatocellular carcinoma (HCC) is critical to improving outcomes since advanced HCC has limited treatment options. Current guidelines recommend HCC ultrasound surveillance every 6 months in high-risk patients however the sensitivity for detecting early stage HCC in clinical practice is poor. Blood-based biomarkers are a promising direction since they are more easily standardized and less resource intensive.
View Article and Find Full Text PDFPredicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test.
Aliment Pharmacol Ther
April 2021
Baylor University Medical Center, Dallas, TX, USA.
Article Synopsis
- Early identification of decompensation risk in stable cirrhotic patients aids in timely interventions and effective referrals from primary care to specialty care.
- The study evaluates the HepQuant-SHUNT test’s ability to predict decompensation, liver transplantation, hospitalization, or liver-related death in patients with compensated cirrhosis.
- Findings show that a Disease Severity Index (DSI) score of 24 or higher is strongly associated with higher risks of adverse outcomes, indicating the SHUNT test's potential as a noninvasive predictive tool for liver health.
Evaluating longitudinal markers under two-phase study designs.
Biostatistics
July 2019
Department of Biostatistics, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA, USA.
Little attention has been given to the design of efficient studies to evaluate longitudinal biomarkers. Measuring longitudinal markers on an entire cohort is cost prohibitive and, especially for rare outcomes such as cancer, may be infeasible. Thus, methods for evaluation of longitudinal biomarkers using efficient and cost-effective study designs are needed.
View Article and Find Full Text PDFA Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers.
Biometrics
March 2018
Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
Advanced hepatocellular carcinoma (HCC) has limited treatment options and poor survival, therefore early detection is critical to improving the survival of patients with HCC. Current guidelines for high-risk patients include ultrasound screenings every six months, but ultrasounds are operator dependent and not sensitive for early HCC. Serum α-Fetoprotein (AFP) is a widely used diagnostic biomarker, but it has limited sensitivity and is not elevated in all HCC cases so, we incorporate a second blood-based biomarker, des'γ carboxy-prothrombin (DCP), that has shown potential as a screening marker for HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!